The Seres Therapeutics Inc. (MCRB) Shares Sold by Rock Springs Capital Management LP

The Seres Therapeutics Inc. (MCRB) Shares Sold by Rock Springs Capital Management LP

Rock Springs Capital Management LP lowered its stake in Seres Therapeutics Inc. (NASDAQ:MCRB) by 16.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 220,000 shares of the company’s stock after selling 42,000 shares during the period. Rock Springs Capital Management LP’s holdings in Seres Therapeutics were worth $2,704,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Rhumbline Advisers raised its stake in Seres Therapeutics by 1.9% in the third quarter. Rhumbline Advisers now owns 15,732 shares of the company’s stock valued at $193,000 after buying an additional 300 shares during the period. California State Teachers Retirement System raised its stake in shares of Seres Therapeutics by 0.8% in the third quarter. California State Teachers Retirement System now owns 37,680 shares of the company’s stock valued at $463,000 after buying an additional 300 shares during the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Seres Therapeutics by 2.6% in the second quarter. Parametric Portfolio Associates LLC now owns 18,928 shares of the company’s stock valued at $550,000 after buying an additional 476 shares during the last quarter. ProShare Advisors LLC raised its stake in shares of Seres Therapeutics by 5.5% in the second quarter. ProShare Advisors LLC now owns 31,599 shares of the company’s stock valued at $918,000 after buying an additional 1,640 shares during the last quarter. Finally, American International Group Inc. raised its stake in shares of Seres Therapeutics by 106.4% in the second quarter. American International Group Inc. now owns 10,262 shares of the company’s stock valued at $298,000 after buying an additional 5,290 shares during the last quarter. 77.20% of the stock is currently owned by hedge funds and other institutional investors.

Seres Therapeutics Inc. (NASDAQ:MCRB) traded down 2.39% during trading on Thursday, hitting $10.23. The stock had a trading volume of 75,684 shares. Seres Therapeutics Inc. has a 12-month low of $8.05 and a 12-month high of $35.98. The firm’s market cap is $412.83 million. The stock’s 50 day moving average price is $10.15 and its 200 day moving average price is $13.86.

Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Thursday, November 10th. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.04. The company had revenue of $13.02 million for the quarter, compared to analysts’ expectations of $10.38 million. The firm’s revenue was up NaN% on a year-over-year basis. During the same period in the prior year, the company earned ($0.38) earnings per share. On average, analysts anticipate that Seres Therapeutics Inc. will post ($2.40) EPS for the current fiscal year.

Several brokerages have commented on MCRB. Zacks Investment Research raised Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Cantor Fitzgerald set a $16.00 price objective on Seres Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 11th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $28.00.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Want to see what other hedge funds are holding MCRB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Seres Therapeutics Inc. (NASDAQ:MCRB).

Related posts

Leave a Comment